NSAIDs in the acute treatment of migraine: A review of clinical and experimental data

Pharmaceuticals

Volumn 3, Issue 6, 2010, Pages 1966-1987

  Pardutz, Arpad ^a   Schoenen, Jean ^b  

^a UNIVERSITY OF SZEGED   (Hungary)

^b UNIVERSITY OF LIÈGE   (Belgium)

Author keywords

Acetaminophen; Aspirin; Experimental data; Migraine; NSAIDs; Randomized controlled trials

Indexed keywords

ACETYLSALICYLIC ACID; CAFFEINE; CYCLOOXYGENASE 1; CYCLOOXYGENASE 2; DICLOFENAC; DICLOFENAC POTASSIUM; ERGOTAMINE; FLURBIPROFEN; IBUPROFEN; IBUPROFEN ARGININE; KETOPROFEN; KETOROLAC; LYSINE ACETYLSALICYLATE; MEFENAMIC ACID; METOCLOPRAMIDE; NAPROXEN; NONSTEROID ANTIINFLAMMATORY AGENT; PARACETAMOL; PARECOXIB; PETHIDINE; PIRPROFEN; PLACEBO; PROMETHAZINE; PROSTAGLANDIN SYNTHASE INHIBITOR; RIZATRIPTAN; ROFECOXIB; SUMATRIPTAN; TOLFENAMIC ACID; UNINDEXED DRUG; ZOLMITRIPTAN;

ACUTE DRUG ADMINISTRATION; ALLODYNIA; CLINICAL TRIAL; COST EFFECTIVENESS ANALYSIS; DOSE RESPONSE; DRUG ABSORPTION; DRUG DOSAGE FORM COMPARISON; DRUG DOSE COMPARISON; DRUG EFFICACY; DRUG MECHANISM; DRUG MEGADOSE; DRUG POTENCY; DRUG POTENTIATION; DRUG SAFETY; DRUG TARGETING; DRUG TOLERABILITY; EPIGASTRIC PAIN; EVIDENCE BASED MEDICINE; GASTROINTESTINAL HEMORRHAGE; GASTROINTESTINAL SYMPTOM; HEADACHE; HUMAN; LOW DRUG DOSE; MIGRAINE; MONOTHERAPY; NAUSEA AND VOMITING; NOCICEPTIVE RECEPTOR; NONHUMAN; PATHOPHYSIOLOGY; PROTEIN LOCALIZATION; REVIEW; SINGLE DRUG DOSE; SPREADING CORTICAL DEPRESSION; TIME TO MAXIMUM PLASMA CONCENTRATION; TRIGEMINAL NERVE; UNSPECIFIED SIDE EFFECT;

EID: 77954938499     PISSN: None     EISSN: 14248247     Source Type: Journal    
DOI: 10.3390/ph3061966     Document Type: Review

References (130)

1. Diener, H. C.; Katsarava, Z.; Limmroth, V. Current diagnosis and treatment of migraine. Schmerz 2008, 22 (Suppl. 1), 51-58.
2. Headache Classification Subcommittee of the International Headache Society. The international classification of headache disorders. Cephalalgia 2004, 24 (Suppl. 1), 9-160.
3. Lipton, R. B.; Diamond, S.; Reed, M.; Diamond, M. L.; Stewart, W. F. Migraine diagnosis and treatment: Results from the American Migraine Study II. Headache 2001, 41, 638-645.
4. Lipton, R. B.; Scher, A. I.; Steiner, T. J.; Bigal, M. E.; Kolodner, K.; Liberman, J. N.; Stewart, W. F. Patterns of health care utilization for migraine in England and in the United States. Neurology 2003, 60, 441-448.
5. Tulunay, F. C. NSAIDs: Behind the mechanisms of action. Funct. Neurol. 2000, 15 (Suppl. 3), 202-207.
6. Hardman, J. G.; Limbird, L. E.; Goodman Gilman, Alfred, cons. Insel PA Analgesic-antipyretics and antiinflammatory agents and drug employed in the treatment of gout. In Goodman and Gilman's: The Pharmacological Basis for Therapeutics, 9th ed.; McGraw-Hill: New York, NY, USA, 1996; pp. 617-657.
7. Obrien, J. R. Effects of salicylates on human-platelets. CC/Clin. Pract. 1980, 51, 18.
8. Ebersberger, A.; Averbeck, B.; Messlinger, K.; Reeh, P. W. Release of substance P, calcitonin gene-related peptide and prostaglandin E2 from rat dura mater encephali following electrical and chemical stimulation in vitro. Neuroscience 1999, 89, 901-907.
9. Goadsby, P. J.; Edvinsson, L.; Ekman, R. Release of vasoactive peptides in the extracerebral circulation of humans and the cat during activation of the trigeminovascular system. Ann. Neurol. 1988, 23, 193-196.
10. Williamson, D. J.; Hargreaves, R. J. Neurogenic inflammation in the context of migraine. Microsc. Res. Tech. 2001, 53, 167-178.
11. Markowitz, S.; Saito, K.; Moskowitz, M. A. Neurogenically mediated plasma extravasation in dura mater: Effect of ergot alkaloids. A possible mechanism of action in vascular headache. Cephalalgia 1988, 8, 83-91.
12. Williamson, D. J.; Hargreaves, R. J.; Hill, R. G.; Shepheard, S. L. Intravital microscope studies on the effects of neurokinin agonists and calcitonin gene-related peptide on dural vessel diameter in the anaesthetized rat. Cephalalgia 1997, 17, 518-524.
13. Strassman, A. M.; Raymond, S. A.; Burstein, R. Sensitization of meningeal sensory neurons and the origin of headaches. Nature 1996, 384, 560-564.
14. Blau, J. N.; Dexter, S. L. The site of pain origin during migraine attacks. Cephalalgia 1981, 1, 143-147.
15. Zhang, X. C.; Kainz, V.; Jakubowski, M.; Burstein, R.; Strassman, A.; Levy, D. Localization of COX-1 and COX-2 in the intracranial dura mater of the rat. Neurosci. Lett. 2009, 452, 33-36.
16. Ellrich, J.; Schepelmann, K.; Pawlak, M.; Messlinger, K. Acetylsalicylic acid inhibits meningeal nociception in rat. Pain 1999, 81, 7-14.
17. Levy, D.; Zhang, X. C.; Jakubowski, M.; Burstein, R. Sensitization of meningeal nociceptors: Inhibition by naproxen. Eur. J. Neurosci. 2008, 27, 917-922.
18. Buzzi, M. G.; Sakas, D. E.; Moskowitz, M. A. Indomethacin and acetylsalicylic-acid block neurogenic plasma-protein extravasation in rat dura mater. Eur. J. Pharmacol. 1989, 165, 251-258.
19. Schuh-Hofer, S.; Tayefeh, M.; Reuter, U.; Dirnagl, U.; Arnold, G. Effects of parecoxib on plasma protein extravasation and c-fos expression in the rat. Headache 2006, 46, 276-285.
20. Burstein, R.; Yamamura, H.; Malick, A.; Strassman, A. M. Chemical stimulation of the intracranial dura induces enhanced responses to facial stimulation in brain stem trigeminal neurons. J. Neurophysiol. 1998, 79, 964-982.
21. Burstein, R.; Yarnitsky, D.; Goor-Aryeh, I.; Ransil, B. J.; Bajwa, Z. H. An association between migraine and cutaneous allodynia. Ann. Neurol. 2000, 47, 614-624.
22. Jenkins, D. W.; Langmead, C. J.; Parsons, A. A.; Strijbos, P. J. Regulation of calcitonin gene- related peptide release from rat trigeminal nucleus caudalis slices in vitro. Neurosci. Lett. 2004, 366, 241-244.
23. Beiche, F.; Scheuerer, S.; Brune, K.; Geisslinger, G.; Goppelt-Struebe, M. Up-regulation of cyclooxygenase-2 mRNA in the rat spinal cord following peripheral inflammation. FEBS Lett. 1996, 390, 165-169.
24. Goppelt-Struebe, M.; Beiche, F. Cyclooxygenase-2 in the spinal cord: Localization and regulation after a peripheral inflammatory stimulus. Adv. Exp. Med. Biol. 1997, 433, 213-216.
25. Kaube, H.; Hoskin, K. L.; Goadsby, P. J. Intravenous acetylsalicylic-acid inhibits central trigeminal neurons in the dorsal horn of the upper cervical spinal-cord in the cat. Headache 1993, 33, 541-544.
26. Tassorelli, C.; Greco, R.; Armentero, M. T.; Blandini, F.; Sandrini, G.; Nappi, G. A role for brain cyclooxygenase-2 and prostaglandin-E2 in migraine: Effects of nitroglycerin. Int. Rev. Neurobiol. 2007, 82, 373-382.
27. Tassorelli, C.; Joseph, S. A.; Nappi, G. Neurochemical mechanisms of nitroglycerin-induced neuronal activation in rat brain: A pharmacological investigation. Neuropharmacology 1997, 36, 1417-1424.
28. Pardutz, A.; Szatmari, E.; Vecsei, L.; Schoenen, J. Nitroglycerin-induced nNOS increase in rat trigeminal nucleus caudalis is inhibited by systemic administration of lysine acetylsalicylate but not of sumatriptan. Cephalalgia 2004, 24, 439-445.
29. Varga, H.; Pardutz, A.; Vamos, E.; Plangar, I.; Egyud, E.; Tajti, J.; Bari, F.; Vecsei, L. Cox-2 inhibitor attenuates NO-induced nNOS in rat caudal trigeminal nucleus. Headache 2007, 47, 1319-1325.
30. Varga, H.; Pardutz, A.; Vamos, E.; Bohar, Z.; Bago, F.; Tajti, J.; Bari, F.; Vecsei, L. Selective inhibition of cyclooxygenase-2 attenuates nitroglycerin-induced calmodulin-dependent protein kinase II alpha in rat trigeminal nucleus caudalis. Neurosci. Lett. 2009, 451, 170-173.
31. Yang, G. Y.; Lee, M. K.; Bae, Y. C.; Ahn, D. K. Intracisternal administration of COX inhibitors attenuates mechanical allodynia following compression of the trigeminal ganglion in rats. Prog. Neuropsychopharmacol. Biol. Psychiatry 2009, 33, 589-595.
32. Diener, H. C. Positron emission tomography studies in headache. Headache 1997, 37, 622-625.
33. Lance, J. W.; Lambert, G. A.; Goadsby, P. J.; Duckworth, J. W. Brainstem influences on the cephalic circulation: Experimental data from cat and monkey of relevance to the mechanism of migraine. Headache 1983, 23, 258-265.
34. Weiller, C.; May, A.; Limmroth, V.; Juptner, M.; Kaube, H.; Schayck, R. V.; Coenen, H. H.; Diener, H. C. Brain stem activation in spontaneous human migraine attacks. Nat. Med. 1995, 1, 658-660.
35. Breder, C. D.; Smith, W. L.; Raz, A.; Masferrer, J.; Seibert, K.; Needleman, P.; Saper, C. B. Distribution and characterization of cyclooxygenase immunoreactivity in the ovine brain. J. Comp. Neurol. 1992, 322, 409-438.
36. Breder, C. D.; Dewitt, D.; Kraig, R. P. Characterization of inducible cyclooxygenase in rat brain. J. Comp. Neurol. 1995, 355, 296-315.
37. Shin, M. C.; Jang, M. H.; Chang, H. K.; Kim, Y. J.; Kim, E. H.; Kim, C. J. Modulation of cyclooxygenase-2 on glycine- and glutamate-induced ion currents in rat periaqueductal gray neurons. Brain Res. Bull. 2003, 59, 251-256.
38. Vaughan, C. W. Enhancement of opioid inhibition of GABAergic synaptic transmission by cyclo-oxygenase inhibitors in rat periaqueductal grey neurones. Br. J. Pharmacol. 1998, 123, 1479-1481.
39. Leith, J. L.; Wilson, A. W.; Donaldson, L. F.; Lumb, B. M. Cyclooxygenase-1-derived prostaglandins in the periaqueductal gray differentially control C- vs. A-fiber-evoked spinal nociception. J. Neurosci. 2007, 27, 11296-11305.
40. Leao, A. A. P. Spreading depression of activity in cerebral cortex. J. Neurophysiol. 1944, 7, 359-390.
41. Lauritzen, M.; Jorgensen, M. B.; Diemer, N. H.; Gjedde, A.; Hansen, A. J. Persistent oligemia of rat cerebral cortex in the wake of spreading depression. Ann. Neurol. 1982, 12, 469-474.
42. Lauritzen, M. Pathophysiology of the migraine aura. The spreading depression theory. Brain 1994, 117, 199-210.
43. Moskowitz, M. A.; Nozaki, K.; Kraig, R. P. Neocortical spreading depression provokes the expression of c-fos protein-like immunoreactivity within trigeminal nucleus caudalis via trigeminovascular mechanisms. J. Neurosci. 1993, 13, 1167-1177.
44. Bolay, H.; Reuter, U.; Dunn, A. K.; Huang, Z.; Boas, D. A.; Moskowitz, M. A. Intrinsic brain activity triggers trigeminal meningeal afferents in a migraine model. Nat. Med. 2002, 8, 136-142.
45. Kaube, H.; Goadsby, P. J. Anti-migraine compounds fail to modulate the propagation of cortical spreading depression in the cat. Eur. Neurol. 1994, 34, 30-35.
46. Wiedemann, M.; deLima, V; Hanke, W. Effects of antimigraine drugs on retinal spreading depression. Naunyn Schmiedebergs Arch. Pharmacol. 1996, 353, 552-556.
47. Shibata, M.; Leffler, C. W.; Busija, D. W. Pial arteriolar constriction following cortical spreading depression is mediated by prostanoids. Brain Res. 1992, 572, 190-197.
48. Koistinaho, J.; Chan, P. H. Spreading depression-induced cyclooxygenase-2 expression in the cortex. Neurochem. Res. 2000, 25, 645-651.
49. Miettinen, S.; Fusco, F. R.; Yrjanheikki, J.; Keinanen, R.; Hirvonen, T.; Roivainen, R.; Narhi, M.; Hokfelt, T.; Koistinaho, J. Spreading depression and focal brain ischemia induce cyclooxygenase-2 in cortical neurons through N-methyl-D-aspartic acid-receptors and phospholipase A2. Proc. Natl. Acad. Sci. USA 1997, 94, 6500-6505.
50. Yokota, C.; Inoue, H.; Kuge, Y.; Abumiya, T.; Tagaya, M.; Hasegawa, Y.; Ejima, N.; Tamaki, N.; Minematsu, K. Cyclooxygenase-2 expression associated with spreading depression in a primate model. J. Cereb. Blood Flow Metab. 2003, 23, 395-398.
51. Bergström S., Carlson, LA.; Ekelund, LG.; Orö, L. Cardiovascular and metabolic response to infusions of prostaglandin E1 and to simultaneous infusions of noradrenaline and prostaglandin E1 in man. Prostaglandin and related factors 35. Acta Physiol. Scand. 1965, 64, 332-339.
52. Carlson LA, Ekelund, LG.; Orö, L. Clinical and metabolic effects of different doses of prostaglandin E1 in man. Prostaglandin and related factors. Acta Med. Scand. 1968, 183, 423-430.
53. Fitzgerald, G. A.; Friedman, L. A.; Miyamori, I.; Ogrady, J.; Lewis, P. J. Double-blind placebo controlled crossover study of prostacyclin in man. Life Sci. 1979, 25, 665-672.
54. Peatfield, R. C.; Gawel, M. J.; Rose, F. C. Effect of infused prostacyclin in migraine and cluster headache. Headache 1981, 21, 124-124.
55. Wienecke, T.; Olesen, J.; Ashina, M. Prostaglandin I(2) (epoprostenol) triggers migraine-like attacks in migraineurs. Cephalalgia 2010, 30, 179-190.
56. Gobel, H.; Ernst, M.; Jeschke, J.; Keil, R.; Weigle, L. Acetylsalicylic-acid activates antinociceptive brain-stem reflex activity in headache patients and in healthy-subjects. Pain 1992, 48, 187-195.
57. Jurna, I.; Brune, K. Central effect of the nonsteroid antiinflammatory agents, indomethacin, ibuprofen, and diclofenac, determined in c-fiber-evoked activity in single neurons of the rat thalamus. Pain 1990, 41, 71-80.
58. Rosslee, L. M.; Eadie, M. J.; Heazlewood, V.; Tyrer, J. H. The absorption of aspirin in migraine, and the effect of metoclopramide. Clin. Exp. Pharmacol. Physiol. 1983, 10, 669-669.
59. Volans, G. N. Effect of metoclopramide on absorption of effervescent aspirin in migraine. Br. J. Clin. Pharmacol. 1975, 2, 57-63.
60. Gillis, J. C.; Brogden, R. N. Ketorolac-A reappraisal of its pharmacodynamic and pharmacokinetic properties and therapeutic use in pain management. Drugs 1997, 53, 139-188.
61. Henry, P.; Hiesseprovost, O.; Dillenschneider, A.; Ganry, H.; Insuasty, J. Efficacy and tolerance of effervescent aspirin metoclopramide association in the treatment of migraine attack. Presse Med. 1995, 24, 254-258.
62. Kangasniemi, P.; Kaaja, R. Ketoprofen and ergotamine in acute migraine. J. Inter. Med. 1992, 231, 551-554.
63. Larsen, B. H.; Christiansen, L. V.; Andersen, B.; Olesen, J. Randomized double-blind comparison of tolfenamic acid and paracetamol in migraine. Acta Neurol. Scand. 1990, 81, 464-467.
64. Massiou, H.; Serrurier, D.; Lasserre, O.; Bousser, M. G. Effectiveness of oral diclofenac in the acute treatment of common migraine attacks-A double-blind-study vs. placebo. Cephalalgia 1991, 11, 59-63.
65. Tfelthansen, P.; Henry, P.; Mulder, L. J.; Scheldewaert, R. G.; Schoenen, E.; Chazot, G. The effectiveness of combined oral lysine acetylsalicylate and metoclopramide compared with oral sumatriptan for migraine. Lancet 1995, 346, 923-926.
66. Diener, H. C. Efficacy and safety of intravenous acetylsalicylic acid lysinate compared to subcutaneous sumatriptan and parenteral placebo in the acute treatment of migraine. A double- blind, double-dummy, randomized, multicenter, parallel group study. Cephalalgia 1999, 19, 581-588.
67. Tfelthansen, P.; Olesen, J. Effervescent metoclopramide and aspirin (Migravess) vs. effervescent aspirin or placebo for migraine attacks-A double-blind-study. Cephalalgia 1984, 4, 107-111.
68. Lange, R.; Schwarz, J. A.; Hohn, M. Acetylsalicylic acid effervescent 1000 mg (Aspirin (R)) in acute migraine attacks; a multicentre, randomized, double-blind, single-dose, placebo-controlled parallel group study. Cephalalgia 2000, 20, 663-667.
69. MacGregor, E. A.; Dowson, A.; Davies, P. T. G. Mouth-dispersible aspirin in the treatment of migraine: A placebo-controlled study. Headache 2002, 42, 249-255.
70. Kirthi, V.; Derry, S.; Moore, R. A.; McQuay, H. J. Aspirin with or without an antiemetic for acute migraine headaches in adults. Cochrane Database Syst. Rev. 2010, 4, CD008041.
71. Havankakanniainen, H. Treatment of acute migraine attack-Ibuprofen and placebo compared. Headache 1989, 29, 507-509.
72. Kloster, R.; Nestvold, K.; Vilming, S. T. A double-blind-study of ibuprofen vs. placebo in the treatment of acute migraine attacks. Cephalalgia 1992, 12, 169-171.
73. Sandrini, G.; Franchini, S.; Lanfranchi, S.; Granella, F.; Manzoni, G. C.; Nappi, G. Effectiveness of ibuprofen-arginine in the treatment of acute migraine attacks. Int. J. Clin. Pharm. Res. 1998, 18, 145-150.
74. Kellstein, D. E.; Lipton, R. B.; Geetha, R.; Koronkiewicz, K.; Evans, F. T.; Stewart, W. F.; Wilkes, K.; Furey, S. A.; Subramanian, T.; Cooper, S. A. Evaluation of a novel solubilized formulation of ibuprofen in the treatment of migraine headache: A randomized, double-blind, placebo-controlled, dose-ranging study. Cephalalgia 2000, 20, 233-243.
75. Codispoti, J. R.; Prior, M. J.; Fu, M.; Harte, C. M.; Nelson, E. B. Efficacy of nonprescription doses of ibuprofen for treating migraine headache. A randomized controlled trial. Headache 2001, 41, 665-679.
76. Misra, U. K.; Kalita, J.; Yadav, R. K. Rizatriptan vs. ibuprofen in migraine: A randomised placebo-controlled trial. J. Headache Pain 2007, 8, 175-179.
77. Diener, H. C.; Bussone, G.; de Liano, H.; Eikermann, A.; Englert, R.; Floeter, T.; Gallai, V.; Gobel, H.; Hartung, E.; Jimenez, M. D.; Lange, R.; Manzoni, G. C.; Mueller-Schwefe, G.; Nappi, G.; Pinessi, L.; Prat, J.; Puca, F. M.; Titus, F.; Voelker, M. Placebo-controlled comparison of effervescent acetylsalicylic acid, sumatriptan and ibuprofen in the treatment of migraine attacks. Cephalalgia 2004, 24, 947-954.
78. Hamalainen, M. L.; Hoppu, K.; Valkeila, E.; Santavuori, P. Ibuprofen or acetaminophen for the acute treatment of migraine in children: A double-blind, randomized, placebo-controlled, crossover study. Neurology 1997, 48, 103-107.
79. Lewis, D. W.; Kellstein, D.; Dahl, G.; Burke, B.; Frank, L. M.; Toor, S.; Northam, R. S.; White, L. W.; Lawson, L. Children's ibuprofen suspension for the acute treatment of pediatric migraine. Headache 2002, 42, 780-786.
80. Lipton, R. B.; Baggish, J. S.; Stewart, W. F.; Codispoti, J. R.; Fu, M. Efficacy and safety of acetaminophen in the treatment of migraine-Results of a randomized, double-blind, placebocontrolled, population-based study. Arch. Inter. Med. 2000, 160, 3486-3492.
81. Dexter, S. L.; Graham, A. N.; Johnston, E. S.; Ratcliffe, D. M.; Wilkinson, M. I. P. Double-blind controlled-study of paramax in the acute treatment of common and classical migraine. Br. J. Clin. Practice 1985, 39, 388-392.
82. Boureau, F.; Joubert, J. M.; Lasserre, V.; Prum, B.; Delecoeuillerie, G. Double-blind comparison of an acetaminophen 400 mg codeine 25 mg combination vs. aspirin 1000 mg and placebo in acute migraine attack. Cephalalgia 1994, 14, 156-161.
83. Leinisch, E.; Evers, S.; Kaempfe, N.; Kraemer, C.; Sostak, P.; Jurgens, T.; Straube, A.; May, A. Evaluation of the efficacy of intravenous acetaminophen in the treatment of acute migraine attacks: A double-blind, placebo-controlled parallel group multicenter study. Pain 2005, 117, 396-400.
84. Hakkarainen, H.; Vapaatalo, H.; Gothoni, G.; Parantainen, J. Tolfenamic acid is as effective as ergotamine during migraine attacks. Lancet 1979, 2, 326-328.
85. Myllyla, V. V.; Havanka, H.; Herrala, L.; Kangasniemi, P.; Rautakorpi, I.; Turkka, J.; Vapaatalo, H.; Eskerod, O. Tolfenamic acid rapid release versus sumatriptan in the acute treatment of migraine: Comparable effect in a double-blind, randomized, controlled, parallel-group study. Headache 1998, 38, 201-207.
86. Tokola, R. A.; Kangasniemi, P.; Neuvonen, P. J.; Tokola, O. Tolfenamic acid, metoclopramide, caffeine and their combinations in the treatment of migraine attacks. Cephalalgia 1984, 4, 253-263.
87. Hakkarainen, H.; Parantainen, J.; Gothoni, G.; Vapaatalo, H. Tolfenamic acid and caffeine-A useful combination in migraine. Cephalalgia 1982, 2, 173-177.
88. Nestvold, K.; Kloster, R.; Partinen, M.; Sulkava, R. Treatment of acute migraine attack- Naproxen and placebo compared. Cephalalgia 1985, 5, 115-119.
89. Andersson, P. G.; Hinge, H. H.; Johansen, O.; Andersen, C. U.; Lademann, A.; Gotzsche, P. C. Double-blind-study of naproxen vs. placebo in the treatment of acute migraine attacks. Cephalalgia 1989, 9, 29-32.
90. Johnson, E. S.; Ratcliffe, D. M.; Wilkinson, M. Naproxen sodium in the treatment of migraine. Cephalalgia 1985, 5, 5-10.
91. Brandes, J. L.; Kudrow, D.; Stark, S. R.; O'Carroll, C. P.; Adelman, J. U.; O'Donnell, F. J.; Alexander, W. J.; Spruill, S. E.; Barrett, P. S.; Lener, S. E. Sumatriptan-naproxen for acute treatment of migraine: A randomized trial. JAMA 2007, 297, 1443-1454.
92. Landy, S.; Freitag, F.; Smith, T.; Burch, S.; White, J. D.; Runken, M. C. Assessing workplace productivity and activity time in migraineurs treated with a single-tablet of sumatriptan formulated with RT technology (TM) and naproxen sodium (SumaRT/NAP) or placebo. Neurology 2007, 68, A265.
93. Smith, T. R.; Sunshine, A.; Stark, S. R.; Littlefield, D. E.; Spruill, S. E.; Alexander, W. J. Sumatriptan and naproxen sodium for the acute treatment of migraine. Headache 2005, 45, 983-991.
94. Bussone, G.; Grazzi, L.; D'Amico, D.; Manzoni, C.; Granella, F.; Cortelli, P.; Pierangeli, G.; Canal, N.; Colombo, B.; Frediani, F.; Maltempo, C.; Peruzzi, E.; Edson, K.; Ezzet, N.; Huels, J. Acute treatment of migraine attacks: Efficacy and safety of a nonsteroidal anti-inflammatory drug, diclofenac-potassium, in comparison to oral sumatriptan and placebo. Cephalalgia 1999, 19, 232-240.
95. Dahlof, C.; Bjorkman, R. Diclofenac-K (50 and 100 mg) and placebo in the acute treatment of migraine. Cephalalgia 1993, 13, 117-123.
96. McNeely, W.; Goa, K. L. Diclofenac-potassium in migraine-A review. Drugs 1999, 57, 991-1003.
97. Peroutka, S. J.; Lyon, J. A.; Swarbrick, J.; Lipton, R. B.; Kolodner, K.; Goldstein, J. Efficacy of diclofenac sodium softgel 100 mg with or without caffeine 100 mg in migraine without aura: A randomized, double-blind, crossover study. Headache 2004, 44, 136-141.
98. Delbene, E.; Poggioni, M.; Garagiola, U.; Maresca, V. Intramuscular treatment of migraine attacks using diclofenac sodium-A crossover clinical-trial. J. Inter. Med. Res. 1987, 15, 44-48.
99. Schoenen, J.; De Klippel, N.; Giurgea, S.; Herroelen, L.; Jacquy, J.; Louis, P.; Monseu, G.; Vandenheede, M. Almotriptan and its combination with aceclofenac for migraine attacks: A study of efficacy and the influence of auto-evaluated brush allodynia. Cephalalgia 2008, 28, 1095-1105.
100. Kinnunen, E.; Erkinjuntti, T.; Farkkila, M.; Palomaki, H.; Porras, J.; Teirmaa, H.; Freudenthal, Y.; Andersson, P. Placebo-controlled double-blind trial of pirprofen and an ergotamine tartrate compound in migraine attacks. Cephalalgia 1988, 8, 175-179.
101. Awidi, A. S. Efficacy of flurbiprofen in the treatment of acute migraine attacks-A double-blind crossover study. Curr. Ther. Res. 1982, 32, 492-497.
102. Dib, M.; Massiou, H.; Weber, M.; Henry, P.; Garcia-Acosta, S.; Bousser, M. G. Efficacy of oral ketoprofen in acute migraine-A double-blind randomized clinical trial. Neurology 2002, 58, 1660-1665.
103. Karabetsos, A.; Karachalios, G.; Bourlinou, P.; Reppa, A.; Koutri, R.; Fotiadou, A. Ketoprofen vs. paracetamol in the treatment of acute migraine. Headache 1997, 37, 12-14.
104. Silberstein, S.; Tepper, S.; Brandes, J.; Diamond, M.; Goldstein, J.; Winner, P.; Venkatraman, S.; Vrijens, F.; Malbecq, W.; Lines, C.; Visser, W. H.; Reines, S.; Yuen, E. Randomized, placebo- controlled trial of rofecoxib in the acute treatment of migraine. Neurology 2004, 62, 1552-1557.
105. Hakkarainen, H.; Gustafsson, B.; Stockman, O. Comparative trial of ergotamine tartrate, acetyl salicylic-acid and a dextropropoxyphene compound in acute migraine attacks. Headache 1978, 18, 35-39.
106. Hakkarainen, H.; Quiding, H.; Stockman, O. Mild analgesics as an alternative to ergotamine in migraine-A comparative trial with acetylsalicylic-acid, ergotamine tartrate, and a dextropropoxyphene compound. Eur. J. Clin. Pharmacol. 1980, 20, 590-595.
107. Geraud, G.; Compagnon, A.; Rossi, A. Zolmitriptan vs. a combination of acetylsalicylic acid and metoclopramide in the acute oral treatment of migraine: A double-blind, randomised, three- attack study. Eur. Neurol. 2002, 47, 88-98.
108. Pearce, I.; Frank, G. J.; Pearce, J. M. S. Ibuprofen compared with paracetamol in migraine. Practitioner 1983, 227, 465-467.
109. Karachalios, G. N.; Fotiadou, A.; Chrisikos, N.; Karabetsos, A.; Kehagioglou, K. Treatment of acute migraine attack with diclofenac sodium-A double-blind-study. Headache 1992, 32, 98-100.
110. Peatfield, R. C.; Petty, R. G.; Rose, F. C. Double-blind comparison of mefenamic-acid and acetaminophen (Paracetamol) in migraine. Cephalalgia 1983, 3, 129-134.
111. Pradalier, A.; Rancurel, G.; Dordain, G.; Verdure, L.; Rascol, A.; Dry, J. Acute migraine attack therapy-Comparison of naproxen sodium and an ergotamine tartrate compound. Cephalalgia 1985, 5, 107-113.
112. Treves, T. A.; Streiffler, M.; Korczyn, A. D. Naproxen sodium vs. ergotamine tartrate in the treatment of acute migraine attacks. Headache 1992, 32, 280-282.
113. Sargent, J. D.; Baumel, B.; Peters, K.; Diamond, S.; Saper, J. R.; Eisner, L. S.; Solbach, P. Aborting a migraine attack-Naproxen sodium v ergotamine plus caffeine. Headache 1988, 28, 263-266.
114. Larkin, G. L.; Prescott, J. E. A randomized, double-blind, comparative-study of the efficacy of ketorolac tromethamine vs. meperidine in the treatment of severe migraine. Ann. Emerg. Med. 1992, 21, 919-924.
115. Davis, C. P.; Torre, P. R.; Williams, C.; Gray, C.; Barrett, K.; Krucke, G.; Peake, D.; Bass, B. Ketorolac vs. meperidine-plus-promethazine treatment of migraine headache-Evaluations by patients. Amer. J. Emerg. Med. 1995, 13, 146-150.
116. Shrestha, M.; Singh, R.; Moreden, J.; Hayes, J. E. Ketorolac vs. chlorpromazine in the treatment of acute migraine without aura-A prospective, randomized, double-blind trial. Arch. Intern. Med. 1996, 156, 1725-1728.
117. Seim, M. B.; March, J. A.; Dunn, K. A. Intravenous ketorolac vs. intravenous prochlorperazine for the treatment of migraine headaches. Acad. Emerg. Med. 1998, 5, 573-576.
118. Meredith, J. T.; Wait, S.; Brewer, K. L. A prospective double-blind study of nasal sumatriptan vs. IV ketorolac in migraine. Amer. J. Emerg. Med. 2003, 21, 173-175.
119. Sandrini, G.; Cerbo, R.; Del Bene, E.; Ferrari, A.; Genco, S.; Grazioli, I.; Martelletti, P.; Nappi, G.; Pinessi, L.; Sarchielli, P.; Tamburro, P.; Uslenghi, C.; Zanchin, G. Efficacy of dosing and re- dosing of two oral fixed combinations of indomethacin, prochlorperazine and caffeine compared with oral sumatriptan in the acute treatment of multiple migraine attacks: A double-blind, double-dummy, randomised, parallel group, multicentre study. Int. J. Clin. Pract. 2007, 61, 1256-1269.
120. Di Monda, V.; Nicolodi, M.; Aloisio, A.; Del Bianco, P.; Fonzari, M.; Grazioli, I.; Uslenghi, C.; Vecchiet, L.; Sicuteri, F. Efficacy of a fixed combination of indomethacin, prochlorperazine, and caffeine versus sumatriptan in acute treatment of multiple migraine attacks: A multicenter, randomized, crossover trial. Headache 2003, 43, 835-844.
121. Lanas, A.; Garcia-Rodriguez, L. A.; Arroyo, M. T.; Gomollon, F.; Feu, F.; Gonzalez-Perez, A.; Zapata, E.; Bastida, G.; Rodrigo, L.; Santolaria, S.; Guell, M.; de Argila, C. M.; Quintero, E.; Borda, F.; Pique, J. M. Risk of upper gastrointestinal ulcer bleeding associated with selective cyclo-oxygenase-2 inhibitors, traditional non-aspirin non-steroidal anti-inflammatory drugs, aspirin and combinations. Gut 2006, 55, 1731-1738.
122. Lanas, A.; Garcia-Rodriguez, L. A.; Arroyo, M. T.; Gomollon, F.; Zapata, E.; Bujanda, L.; Feu, F.; Quintero, E.; Castro, M.; Santolaria, S. Coxibs, NSAIDs, aspirin, PPIs and the risks of upper GI bleeding in common clinical practice. Gastroenterology 2005, 128, A95.
123. Pradalier, A.; Clapin, A.; Dry, J. Treatment review-Non-steroid anti-inflammatory drugs in the treatment and long-term prevention of migraine attacks. Headache 1988, 28, 550-557.
124. Bombardier, C.; Laine, L.; Reicin, A.; Shapiro, D.; Burgos-Vargas, R.; Davis, B.; Day, R.; Ferraz, M. B.; Hawkey, C. J.; Hochberg, M. C.; Kvien, T. K.; Schnitzer, T. J. Comparison of upper gastrointestinal toxicity of rofecoxib and naproxen in patients with rheumatoid arthritis. VIGOR study group. N. Engl. J. Med. 2000, 343, 1520-1528.
125. Konstam, M. A.; Weir, M. R.; Reicin, A.; Shapiro, D.; Sperling, R. S.; Barr, E.; Gertz, B. J. Cardiovascular thrombotic events in controlled, clinical trials of rofecoxib. Circulation 2001, 104, 2280-2288.
126. Farkouh, M. E.; Greenberg, B. P. An evidence-based review of the cardiovascular risks of nonsteroidal anti-inflammatory drugs. Am. J. Cardiol. 2009, 103, 1227-1237.
127. Bigal, M. E.; Serrano, D.; Buse, D.; Scher, A.; Stewart, W. F.; Lipton, R. B. Acute migraine medications and evolution from episodic to chronic migraine: A longitudinal population-based study. Headache 2008, 48, 1157-1168.
128. Limmroth, V.; Katsarava, Z. Medication overuse headache. Curr. Opin. Neurol. 2004, 17, 301-306.
129. Alahurula, V.; Myllyla, V. V.; Hokkanen, E.; Tokola, O. Tolfenamic acid and ergotamine abuse. Headache 1981, 21, 240-242.
130. Mathew, N. T. Amelioration of ergotamine withdrawal symptoms with naproxen. Headache 1987, 27, 130-133.